JAKARTA -- Indonesia's largest pharmaceuticals manufacturer, Kalbe Farma, has struck a deal with South Korea's Genexine to develop and commercialize a drug candidate for both COVID-19 and cancer treatments.
Kalbe Farma said its licensing agreement with the biotechnology group was worth $1.1 billion, including costs for clinical trials, registration and commercialization as well as royalty payments that will be made in stages to Genexine.
